38.57
0.17 (0.44%)
| Previous Close | 38.40 |
| Open | 38.85 |
| Volume | 3,023,322 |
| Avg. Volume (3M) | 3,114,824 |
| Market Cap | 7,323,709,952 |
| Price / Sales | 30.54 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -2.88 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.74 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 5.48% |
| % Held by Institutions | 92.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 146.31%) | Buy |
| Median | 54.00 (40.01%) | |
| Low | 49.00 (Citigroup, 27.04%) | Buy |
| Average | 60.88 (57.84%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 36.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 30 Apr 2025 | 63.00 (63.34%) | Buy | 38.36 |
| Scotiabank | 30 Apr 2025 | 55.00 (42.60%) | Buy | 38.36 |
| 21 Feb 2025 | 52.00 (34.82%) | Buy | 36.85 | |
| UBS | 30 Apr 2025 | 72.00 (86.67%) | Buy | 38.36 |
| HC Wainwright & Co. | 15 Apr 2025 | 53.00 (37.41%) | Buy | 34.24 |
| 13 Feb 2025 | 49.00 (27.04%) | Buy | 31.56 | |
| Redburn Atlantic | 31 Mar 2025 | 50.00 (29.63%) | Buy | 34.57 |
| JP Morgan | 24 Mar 2025 | 50.00 (29.63%) | Buy | 37.22 |
| Cantor Fitzgerald | 21 Feb 2025 | 95.00 (146.31%) | Buy | 36.85 |
| Citigroup | 21 Feb 2025 | 49.00 (27.04%) | Buy | 36.85 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |